Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Convalescence plasma treatment of COVID-19 : results from a prematurely terminated randomized controlled open-label study in Southern Sweden

Holm, Karin LU ; Lundgren, Maria N LU ; Kjeldsen-Kragh, Jens LU ; Ljungquist, Oskar LU ; Böttiger, Blenda LU ; Wikén, Christian ; Öberg, Jonas LU orcid ; Fernström, Nils ; Rosendal, Ebba and Överby, Anna K LU , et al. (2021) In BMC Research Notes 14. p.1-5
Abstract

OBJECTIVE: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19.

RESULTS: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated... (More)

OBJECTIVE: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19.

RESULTS: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6-15) for the convalescent plasma group and 7 days (IQR 5-9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08-2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC Research Notes
volume
14
article number
440
pages
1 - 5
publisher
BioMed Central (BMC)
external identifiers
  • pmid:34863304
  • scopus:85120748357
ISSN
1756-0500
DOI
10.1186/s13104-021-05847-7
language
English
LU publication?
yes
additional info
© 2021. The Author(s).
id
20148598-9f00-4307-b1c6-e7b7a174a3ce
date added to LUP
2021-12-09 22:15:01
date last changed
2024-06-21 02:16:00
@article{20148598-9f00-4307-b1c6-e7b7a174a3ce,
  abstract     = {{<p>OBJECTIVE: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19.</p><p>RESULTS: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6-15) for the convalescent plasma group and 7 days (IQR 5-9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08-2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020.</p>}},
  author       = {{Holm, Karin and Lundgren, Maria N and Kjeldsen-Kragh, Jens and Ljungquist, Oskar and Böttiger, Blenda and Wikén, Christian and Öberg, Jonas and Fernström, Nils and Rosendal, Ebba and Överby, Anna K and Wigren Byström, Julia and Forsell, Mattias and Landin-Olsson, Mona and Rasmussen, Magnus}},
  issn         = {{1756-0500}},
  language     = {{eng}},
  pages        = {{1--5}},
  publisher    = {{BioMed Central (BMC)}},
  series       = {{BMC Research Notes}},
  title        = {{Convalescence plasma treatment of COVID-19 : results from a prematurely terminated randomized controlled open-label study in Southern Sweden}},
  url          = {{http://dx.doi.org/10.1186/s13104-021-05847-7}},
  doi          = {{10.1186/s13104-021-05847-7}},
  volume       = {{14}},
  year         = {{2021}},
}